Keay Nakae

Chardan Capital | Healthcare

Keay Nakae is an analyst from Chardan Capital specializing in the Healthcare sector. Ranked #228 out of 4553 analysts, they have issued 69 stock ratings with a success rate of 91.37% and an average return of 61.51%.

Keay Nakae has a well-established track record, with 69 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 91.37% and an average return of 61.51%, underscoring their expertise and ability to identify winning opportunities for investors.

#228

Out of 4553

69

Total Ratings

+91.37%

Success Rate

+61.51%

Average Return

Recent Ratings Analysis

ALUR

Feb 24, 2026

Target

$3.00

Current

$1.23

Performance

-9.56%

Keay Nakae rated ALUR as Buy on Feb 24, 2026, setting a price target of 3. The stock has underperformed, dropping 9.56% despite the bullish target of 3.

ALNY

Feb 13, 2026

Target

$475.00

Current

$327.36

Performance

4.12%

On Feb 13, 2026, ALNY was given a Buy rating by Keay Nakae, with a target price of 475. The stock traded sideways with a 4.12% move, keeping the bullish thesis unresolved.

IBIO

Feb 12, 2026

Target

$5.00

Current

$2.87

Performance

36.02%

IBIO received a Buy rating from Keay Nakae on Feb 12, 2026, aiming for 5. Momentum has favored the Buy call, with shares climbing from 2.87 to 2.87, rewarding those who trusted the recommendation.

MNPR

Jan 29, 2026

Target

$100.00

Current

$55.62

Performance

-17.40%

On Jan 29, 2026, Keay Nakae published a Buy outlook on MNPR, with a target of 100. Market action contradicted the Buy thesis, as shares slipped to 55.62.

KRRO

Jan 29, 2026

Target

$15.00

Current

$12.14

Performance

-8.79%

Keay Nakae on Jan 29, 2026 assigned KRRO a Buy rating, with a price target of 15. The call has struggled to gain traction, with shares losing 8.79%.

COYA

Jan 08, 2026

Target

$14.00

Current

$5.05

Performance

-1.37%

On Jan 08, 2026, Keay Nakae reaffirmed COYA with a Buy rating, targeting 14. Market indecision has kept the 14 target in a holding pattern.

ARWR

Jan 07, 2026

Target

$80.00

Current

$61.62

Performance

-6.20%

ARWR was rated Buy by Keay Nakae on Jan 07, 2026, with a price objective of 80. This case shows how bullish projections can fail, with the stock now below 61.615.

RVPH

Jan 05, 2026

Target

$2.00

Current

$0.22

Performance

-33.50%

On Jan 05, 2026, Keay Nakae initiated coverage on RVPH with a Buy rating and target of 2. The Buy call has yet to be validated as shares remain 1.78 away from the target.

STOK

Jan 05, 2026

Target

$35.00

Current

$35.50

Performance

9.06%

Keay Nakae issued a Buy recommendation for STOK on Jan 05, 2026, price target set at 35. Investors following the Buy call captured upside momentum, with shares now at 35.5.

ANRO

Jan 05, 2026

Target

$30.00

Current

$18.99

Performance

14.88%

On Jan 05, 2026, ANRO was evaluated by Keay Nakae, who gave a Buy rating and target of 30. This case illustrates how a timely bullish rating can translate into tangible gains of 14.88%.

SABS

Dec 18, 2025

Target

$12.00

Current

$3.93

Performance

%

Keay Nakae rated SABS as Buy on Dec 18, 2025, setting a price target of 12. Shares have remained stable near 3.93, leaving the 12 target still in play.

DYN

Dec 09, 2025

Target

$38.00

Current

$16.09

Performance

-12.74%

On Dec 09, 2025, DYN was given a Buy rating by Keay Nakae, with a target price of 38. Despite the Buy call, shares fell from 16.09 to 16.09, challenging the optimistic stance.

ABUS

Nov 14, 2025

Target

$5.00

Current

$4.60

Performance

1.77%

ABUS received a Buy rating from Keay Nakae on Nov 14, 2025, aiming for 5. Price action was muted, as shares hovered around 4.6 despite the bullish outlook.

OBIO

Nov 13, 2025

Target

$20.00

Current

$4.35

Performance

4.07%

On Nov 13, 2025, Keay Nakae published a Buy outlook on OBIO, with a target of 20. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 4.35.

RNA

Nov 11, 2025

Target

$72.00

Current

$72.80

Performance

2.97%

Keay Nakae on Nov 11, 2025 assigned RNA a Neutral rating, with a price target of 72. The Hold stance reflected consolidation, as shares held near 72.8.

PRQR

Nov 04, 2025

Target

$4.00

Current

$1.54

Performance

-35.29%

On Nov 04, 2025, Keay Nakae reaffirmed PRQR with a Buy rating, targeting 4. Shares slid 35.29% despite the recommendation, highlighting downside risks.

SLN

Aug 08, 2025

Target

$35.00

Current

$5.35

Performance

6.15%

SLN was rated Buy by Keay Nakae on Aug 08, 2025, with a price objective of 35. A bullish response from the market helped close the gap of 29.65 to the target.

SONN

Apr 07, 2025

Target

$20.00

Current

$1.26

Performance

5.00%

On Apr 07, 2025, Keay Nakae initiated coverage on SONN with a Buy rating and target of 20. Neutral price movement of 5.00% leaves room for interpretation.

GANX

Mar 28, 2025

Target

$6.00

Current

$2.52

Performance

33.33%

Keay Nakae issued a Buy recommendation for GANX on Mar 28, 2025, price target set at 6. Investors following the Buy call captured upside momentum, with shares now at 2.52.

MCRB

Mar 20, 2025

Target

$1.25

Current

$8.89

Performance

-39.28%

On Mar 20, 2025, MCRB was evaluated by Keay Nakae, who gave a Buy rating and target of 1.25. Investors saw limited payoff as shares fell short of the 1.25 target.

FEMY

Nov 13, 2024

Target

$8.00

Current

$0.56

Performance

-45.18%

Keay Nakae rated FEMY as Buy on Nov 13, 2024, setting a price target of 8. The stock has underperformed, dropping 45.18% despite the bullish target of 8.

OMGA

May 07, 2024

Target

$7.00

Current

$0.14

Performance

-93.37%

On May 07, 2024, OMGA was given a Buy rating by Keay Nakae, with a target price of 7. Despite the Buy call, shares fell from 0.1426 to 0.1426, challenging the optimistic stance.

Frequency Asked Questions

Who is Keay Nakae?

Keay Nakae is an analyst from Chardan Capital specializing in the Healthcare sector.

What is Keay Nakae's success rate?

Keay Nakae currently has a success rate of +91.37%.

How many ratings has Keay Nakae issued?

Keay Nakae has issued 69 stock ratings so far.

What is the average return of Keay Nakae's calls?

Their stock ratings have generated an average return of +61.51%.

What is Keay Nakae's ranking?

Keay Nakae is ranked #228 out of 4553 analysts.

What types of ratings does Keay Nakae give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Keay Nakae?

You can follow Keay Nakae by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Keay Nakae?

Their latest rating was a Buy on ALUR issued on 2026-02-24.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep